The landscape of therapeutic development is shifting toward the microbiome. As we move beyond traditional supplementation, the demand for high-precision, functionalized microbial strains has never been greater. Creative Biolabs specializes in the advanced genetic engineering of probiotic strains, offering a comprehensive platform for researchers and pharmaceutical innovators to design, build, and test custom-modified microorganisms. Whether your goal is to track colonization in vivo, enhance a specific metabolic pathway, or silence a competing gene, our genetic engineering suite provides the tools to transform standard probiotics into potent therapeutic engines.
Standard "off-the-shelf" probiotics often fall short in specialized clinical or industrial research. Our Genetically Modified Probiotics (GMPP) platform bridges this gap by applying synthetic biology techniques to well-characterized probiotic chassis.
We offer a vertically integrated workflow that begins with strain selection and moves through in silico design, genomic editing, and rigorous phenotyping. Our expertise covers a wide array of Gram-positive and Gram-negative beneficial bacteria, ensuring that your custom strain retains its viability and safety profile while gaining new, targeted functionalities.
While we can work with client-provided proprietary strains, we maintain an extensive library of well-characterized "chassis" organisms that are optimized for genetic manipulation:
Precise deletion of genes to study function or insertion of exogenous DNA for novel trait expression.
Optimizing promoter strength and plasmid copy numbers to maximize the production of beneficial metabolites or therapeutic proteins.
Integrating GFP, or luciferase tags for real-time tracking of strain localization and survival within animal models.
Fine-tuning enzyme kinetics or enhancing acid/bile tolerance for superior gut persistence.
Traditional probiotic research is often limited by the natural capabilities of the strain. Genetic modification removes these biological "ceilings."
We can engineer strains to express protective coatings or stress-response genes, ensuring higher survival rates through the gastric environment.
Transform a probiotic into a "living pharmacy" that produces anti-inflammatory cytokines, antioxidants, or antimicrobial peptides only when it reaches the target site (e.g., the colon).
By using fluorescently labeled strains, researchers can obtain high-resolution data on colonization patterns, reducing the "guesswork" in pharmacokinetic studies.
We can eliminate unwanted side-products (like D-lactate) or enhance the production of Short-Chain Fatty Acids (SCFAs) to meet specific therapeutic markers.
Our modifications are performed using "food-grade" selection markers or markerless integration techniques to align with biosafety standards and future clinical transitions.
The versatility of customized probiotics allows them to serve multiple sectors:
Custom strains serve as Live Biotherapeutic Products (LBPs). By engineering E. coli Nissle 1917 to express phenylalanine-degrading enzymes, for example, researchers can develop treatments for metabolic diseases like PKU.
Use Gene Knockout services to identify which specific bacterial genes are responsible for cross-talk with the host immune system. This allows for a "reductionist" approach to complex microbiome interactions.
Engineered probiotics can act as biosensors, designed to fluoresce or produce a detectable signal in the presence of specific biomarkers (e.g., inflammation markers or heme), providing a non-invasive look at gut health.
Developing strains for the agricultural sector that overexpress phytase or cellulase to improve feed efficiency and reduce environmental nitrogen output.
Modern microbiome challenges require more than just "good bacteria"—they require smart bacteria. Our team of molecular biologists and bioinformaticians is ready to help you design a strain that meets your exact specifications.
We employ a variety of tools depending on the strain, including gene editing/Cas12a, Lambda-Red recombineering, and traditional homologous recombination via suicide plasmids. For industrial applications, we prioritize markerless integration to ensure the final product is antibiotic-resistance gene-free.
Yes. For long-term stability, we recommend genomic integration rather than plasmid-based expression. We can perform stability testing over 50+ generations to ensure the phenotype remains consistent.
We can engineer "kill switches" or auxotrophic requirements (where the bacteria require a specific, non-natural nutrient to survive) to ensure the strain does not persist in the environment after it has performed its function.
A standard knockout or fluorescent labeling project typically takes 4 to 8 weeks, including design, transformation, and validation via Sanger sequencing.
We can deliver your custom strains as glycerol stocks, lyophilized (freeze-dried) powder, or active cultures, depending on your downstream application requirements.
Copyright © 2026 Creative Biolabs. All Rights Reserved.